Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	0.14
Equity-to-Asset	0.27
Debt-to-Equity	1.71
Debt-to-EBITDA	5.81
Interest Coverage	2.11
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.07	Distress Grey Safe
Beneish M-Score	-2.84	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	42.7
	3-Year EBITDA Growth Rate	40.7
	3-Year EPS without NRI Growth Rate	-13.8
	3-Year FCF Growth Rate	29.4
	3-Year Book Growth Rate	26.1
	Future 3-5Y EPS without NRI Growth Rate Estimate	42.63
	Future 3-5Y Total Revenue Growth Rate Estimate	7.25

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	48
	9-Day RSI	51.03
	14-Day RSI	51.31
	6-1 Month Momentum %	-30.09
	12-1 Month Momentum %	-26.77

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.91
	Quick Ratio	1.05
	Cash Ratio	0.57
	Days Inventory	209.27
	Days Sales Outstanding	40.24
	Days Payable	82.99

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.38
	Dividend Payout Ratio	0.65
	3-Year Dividend Growth Rate	59.9
	Forward Dividend Yield %	0.38
	5-Year Yield-on-Cost %	1.21
	Shareholder Yield %	-17.49

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	44.16
	Operating Margin %	14
	Net Margin %	2.32
	FCF Margin %	10.48
	ROE %	3.36
	ROA %	0.82
	ROIC %	3.83
	3-Year ROIIC %	0.99
	ROC (Joel Greenblatt) %	15.49
	ROCE %	5.06
	Years of Profitability over Past 10-Year	10

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	171.86
	Forward PE Ratio	36.54
	PE Ratio without NRI	171.86
	Shiller PE Ratio	54.16
	Price-to-Owner-Earnings	48.18
	PEG Ratio	3.45
	PS Ratio	3.96
	PB Ratio	4.92
	Price-to-Free-Cash-Flow	38.01
	Price-to-Operating-Cash-Flow	15.81
	EV-to-EBIT	46.59
	EV-to-Forward-EBIT	29.58
	EV-to-EBITDA	24.01
	EV-to-Forward-EBITDA	18.84
	EV-to-Revenue	5.72
	EV-to-Forward-Revenue	5.13
	EV-to-FCF	54.56
	Price-to-Projected-FCF	2.34
	Price-to-DCF (Earnings Based)	4.5
	Price-to-DCF (FCF Based)	1
	Price-to-Median-PS-Value	0.77
	Price-to-Peter-Lynch-Fair-Value	8.04
	Earnings Yield (Greenblatt) %	2.15
	FCF Yield %	2.32
	Forward Rate of Return (Yacktman) %	22.11

GF Value: €264.21

STU:SRT

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with SRT. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.